PRP treatments have been effective for the user, with a new recommendation of using a high-quality plasma kit once a year. The user seeks experiences with this specific PRP approach.
A 26-year-old man with diffuse alopecia is using electric scalp massage, dermastamp, and multivitamins for treatment but is intolerant to finasteride. A dermatologist recommended PRP and mesotherapy with exosomes and dutasteride.
A user is seeking advice on increasing graft survivability after a hair transplant, mentioning PRP, Mesotherapy, StemCell injections, and considering L-Arginine before starting Minoxidil. They are looking for ways to support blood flow before applying Minoxidil.
Dutasteride mesotherapy is discussed as a potentially effective hair loss treatment with no sexual side effects, requiring less frequent application than daily pills. However, it is not widely popular due to limited availability, high cost, and skepticism about its effectiveness.
The post discusses using at-home Dutasteride mesotherapy for hair loss, combined with topical minoxidil, microneedling, and a red laser cap. The user reports initial shedding, thicker hair, and a temporary dip in libido as side effects.
Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.
A human trial involving verteporfin for hair regeneration, with the results showing some regrowth of 1-2 hairs in an area where a follicular unit was extracted. The conversation also suggested that future studies should involve higher doses and more frequent injections.
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
The conversation is about DIY Dutasteride mesotherapy for hair loss, focusing on creating an injectable treatment to target the scalp and limit side effects. The user seeks feedback on enhancing the treatment with additional ingredients.
HairClone is offering a Dermal Papilla Cell Hair Multiplication procedure in Guatemala, raising questions about its effectiveness and regulatory reasons for the location. Users express skepticism and curiosity about the treatment's success and potential costs.
The conversation is about finding the best method to lower scalp prolactine, with suggestions like P5P and Melatonin. The user also mentions HMI115 as a potential treatment and seeks feedback from those who have tried these methods.
Recruitment for a verteporfin trial and a separate hair cloning trial using verteporfin and other methods is underway, with locations in Jordan, NYC, Beverly Hills, and Memphis. Dr. Bloxham is conducting the hair cloning trial, and interested participants are encouraged to contact him directly.
Amplifica starting clinical trials for new hair loss drug. SCUBE3 protein discovered, stimulates hair growth, could be alternative to Minoxidil and Finasteride.
The conversation discusses experiences with Dutasteride Mesotherapy for hair loss. Users share their results and compare it to other treatments like Minoxidil and Finasteride.
Microneedling and Platelet-Rich Plasma (PRP) are equally effective for treating androgenetic alopecia, with no additional benefits from PRP over microneedling. Both treatments are safe and well-tolerated.
Verteporfin is being explored for hair regeneration, with unofficial trials and updates shared online. Efforts are being made to encourage more surgeons to trial verteporfin for donor hair regeneration.
DHT causes hair loss by driving cells into senescence, and a polyphenol in black chokeberry may reverse this. A product using this theory is being considered for use alongside finasteride, minoxidil, and microneedling.
The conversation is about the potential of the RCH-01/Replicel hair loss treatment and its lack of updates since 2013, with the user expressing hope for its success and considering using Minoxidil, finasteride, and dermarolling in the meantime. Other treatments mentioned as promising are Breezula and Tsuji.
The conversation is about a user considering reducing their dutasteride dose due to side effects like lower libido and watery semen. They plan to use dutasteride mesotherapy every three months to maintain hair while reducing systemic DHT suppression.
TGF-B affects hair growth, both causing stemcell division and death depending on amounts. Amplifica's treatment injects Scube3 to increase TGF-B for hair growth.
Dutasteride mesotherapy is being considered for hair regrowth, with one user reporting significant success when combined with oral dutasteride, oral and topical minoxidil, and vitamins. Another user suggests using topical finasteride and oral dutasteride instead, as mesotherapy results are inconclusive.
A user proposed genetically engineering scalp stem cells to stop androgen receptors from causing hair loss. Others discussed the feasibility, existing research, and potential issues with this approach, including targeting the correct cells and unintended effects.
OP is considering dutasteride mesotherapy for hair loss after experiencing side effects from finasteride. A user shared their experience, stating that the treatment was ineffective and costly.
A user is exploring VEGF gene therapy to enhance hair transplant results, considering measuring hair shaft diameter and growth rate. Suggestions include using phototrichograms and possibly adding PRP, though its effectiveness is uncertain.
A compound called MTP3 from the Monoterpene family was found to be safe and highly effective at treating hair loss by inhibiting the FGF5 gene, but its identity is undisclosed for commercial reasons. No specific treatments like Minoxidil, finasteride, or RU58841 were discussed.
MCL-1 protein may help maintain hair follicles in the growth phase and prevent miniaturization. There is interest in experimental treatments like exosomes, peptides, or stemcell serums to upregulate MCL-1 for hair loss, especially for those not using minoxidil or finasteride.
AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.